drugset / Trial / NCT04476459
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
Timeline
- Start
- 2020-07-23
- Primary completion
- 2022-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |